Most studied
mRNA & LNP vaccines
Stabilize lipid nanoparticles without lipid fusion, RNA hydrolysis or particle aggregation — eliminating the −80 °C constraint.
Applications
One platform, every modality.
AmberVax has been validated across the full breadth of modern biological drug substances — from fragile mRNA-lipid nanoparticle complexes to live attenuated organisms.
AAV · Ad
Viral vector vaccines
AAV, adenovirus and other viral vectors retain infectious titer through ambient storage, simplifying gene-therapy logistics.
Subunit
Protein subunit vaccines
Preserve native fold and epitope presentation for recombinant antigens, including conformationally sensitive trimers.
Biologics
Monoclonal antibodies
Stabilize high-concentration mAb formulations against aggregation, supporting prefilled solid formats and self-administration.
Live attenuated
Live attenuated organisms
Maintain viability of live attenuated bacterial and viral vaccines at temperatures well above the cold chain threshold.
Emerging
Cell-derived biologics
Adjacent applications in extracellular vesicles, cell-derived therapeutics and reagent-grade biomolecules.